NFX88
Neuropathic pain from spinal cord injury
Phase 2Active
Key Facts
About Neurofix
Neurofix Pharma is a private, clinical-stage biotech based in Madrid and Salamanca, Spain, developing small molecule therapeutics for neurological conditions. Its lead program, NFX88, is poised to enter final-phase clinical trials for spinal cord injury-related neuropathic pain, having cleared a Phase IIA study. The company is backed by a mix of public grants, institutional loans, and private investment, including from the Matutes family office, and is actively engaging with the European biotech community to advance its pipeline.
View full company profile